Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)

 

Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial

Flaherty KR et al.
 

Acceder

Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?

Chaudhuri N et al.
 

Acceder

Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial

Valenzuela C et al.
 

Acceder

 

 

Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib?

Richeldi L et al.
 

Acceder

Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs)

Bonella F et al.
 

Acceder

King’s Brief Interstitial Lung Disease (K-BILD) questionnaire: content relevance in progressive fibrosing ILD (PF-ILD)

Birring SS et al.
 

Acceder

 

 

Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry

Griese M et al.
 

Acceder